PDE9 inhibitors for treating cardiovascular disorders
The invention relates to PDE9 inhibitors for treating cardiovascular disorders. Preferred PDE9 inhibitors are compounds of formula I wherein R1 is H or C1-6 alkyl, wherein R1 is attached to either N1 or N2; R2 is C1-6 alkyl optionally substituted by hydroxy or alkoxy; C3-7 cycloalkyl optionally substituted by alkyl, hydroxy or alkoxy; a saturated 5-6-membered heterocycle optionally substituted by alkyl, hydroxy or alkoxy; het1 or Ar1; R3 is C1-6 alkyl optionally substituted by 1 or 2 groups independently selected from: Ar2; C3-7cycloalkyl optionally substituted by C1-6alkyl; OAr2; SAr2; NHC(O)C1-6 alkyl; het2; xanthene; and naphthalene.
-
(2008/06/13)
SYNTHESIS OF ORGANIC SULFUR COMPOUNDS BY MEANS OF SILICON-CONTAINING REAGENTS
-
Mizhiritskii, M. D.,Reikhsfel'd, V. O.
p. 1373 - 1382
(2007/10/02)
More Articles about upstream products of 16670-48-7